Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation

Annals of Oncology

Volumn 17, Issue SUPPL. 4, 2006, Pages

  Moskowitz, C H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Autologous stem cell transplantation; Diffuse large B cell lymphoma (DLBCL); DNA microarray; ICE (ifosfamide, carboplatin, etoposide) regimen; Prognostic factors; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; KI 67 ANTIGEN; MESNA; MUCIN 1; MULTIDRUG RESISTANCE PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; DRUG MEGADOSE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LONG TERM CARE; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33646895826     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj998     Document Type: Conference Paper

References (9)

1. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin and etoposide: A highly effective cytoreductive and peripheral blood cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-3785.
2. Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684-3688.
3. Hagberg H, Gisselbrecht C. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: An update of the CORAL study. Ann Oncol 2006; Supp 4: Iv27-28.
4. Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann Oncol 2003; 14 (Suppl 1): I17-i20.
5. Kewalramani T, Zelenetz AD, Hedrick EE et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin's lymphoma: An intent-to-treat analysis. Blood 2000; 96: 2399-3404.
6. Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplant outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996.
7. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. New Engl J Med 2002; 346: 1937-1947.
8. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
9. Hedvat CV, Hegde A, Chaganti RS et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Human Path 2002; 3: 968-974.